B. Riley Asset Management LLC Takes $4.28 Million Position in Harvard Bioscience, Inc. (NASDAQ:HBIO)

B. Riley Asset Management LLC bought a new stake in shares of Harvard Bioscience, Inc. (NASDAQ:HBIOGet Rating) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 606,394 shares of the medical instruments supplier’s stock, valued at approximately $4,275,000. Harvard Bioscience comprises approximately 1.9% of B. Riley Asset Management LLC’s investment portfolio, making the stock its 11th biggest holding. B. Riley Asset Management LLC owned 1.49% of Harvard Bioscience at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Citigroup Inc. boosted its holdings in Harvard Bioscience by 146.3% during the 3rd quarter. Citigroup Inc. now owns 4,512 shares of the medical instruments supplier’s stock valued at $31,000 after acquiring an additional 2,680 shares during the period. Royal Bank of Canada boosted its holdings in Harvard Bioscience by 47.6% during the 3rd quarter. Royal Bank of Canada now owns 4,452 shares of the medical instruments supplier’s stock valued at $31,000 after acquiring an additional 1,435 shares during the period. Altshuler Shaham Ltd purchased a new position in Harvard Bioscience during the 3rd quarter valued at $43,000. BNP Paribas Arbitrage SA boosted its holdings in Harvard Bioscience by 488.1% during the 3rd quarter. BNP Paribas Arbitrage SA now owns 7,551 shares of the medical instruments supplier’s stock valued at $53,000 after acquiring an additional 6,267 shares during the period. Finally, Morgan Stanley boosted its holdings in Harvard Bioscience by 15.2% during the 3rd quarter. Morgan Stanley now owns 9,746 shares of the medical instruments supplier’s stock valued at $69,000 after acquiring an additional 1,289 shares during the period. 72.75% of the stock is currently owned by hedge funds and other institutional investors.

Shares of NASDAQ HBIO traded up $0.04 during mid-day trading on Friday, reaching $3.78. 313,632 shares of the company were exchanged, compared to its average volume of 262,274. The company has a quick ratio of 1.13, a current ratio of 2.18 and a debt-to-equity ratio of 0.61. The stock has a market cap of $155.89 million, a price-to-earnings ratio of -23.62 and a beta of 1.84. Harvard Bioscience, Inc. has a 1 year low of $3.36 and a 1 year high of $8.75. The firm has a 50-day moving average of $5.63 and a 200 day moving average of $6.21.

Harvard Bioscience (NASDAQ:HBIOGet Rating) last issued its quarterly earnings data on Wednesday, May 4th. The medical instruments supplier reported $0.04 earnings per share for the quarter, missing analysts’ consensus estimates of $0.05 by ($0.01). Harvard Bioscience had a positive return on equity of 9.06% and a negative net margin of 5.38%. During the same period in the previous year, the firm earned $0.03 EPS. On average, equities analysts forecast that Harvard Bioscience, Inc. will post 0.26 earnings per share for the current year.

Several brokerages have weighed in on HBIO. StockNews.com began coverage on Harvard Bioscience in a report on Thursday, March 31st. They issued a “hold” rating for the company. Zacks Investment Research upgraded Harvard Bioscience from a “sell” rating to a “hold” rating in a report on Wednesday.

In other Harvard Bioscience news, CEO James W. Green bought 30,000 shares of Harvard Bioscience stock in a transaction that occurred on Friday, May 6th. The shares were bought at an average cost of $3.78 per share, with a total value of $113,400.00. Following the transaction, the chief executive officer now directly owns 2,309,955 shares of the company’s stock, valued at approximately $8,731,629.90. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO James W. Green bought 10,000 shares of Harvard Bioscience stock in a transaction that occurred on Monday, May 9th. The shares were acquired at an average cost of $3.40 per share, for a total transaction of $34,000.00. Following the completion of the transaction, the chief executive officer now directly owns 2,319,955 shares in the company, valued at $7,887,847. The disclosure for this purchase can be found here. Corporate insiders own 6.20% of the company’s stock.

Harvard Bioscience Company Profile (Get Rating)

Harvard Bioscience, Inc develops, manufactures, and sells technologies, products, and services that enables fundamental research, discovery, and pre-clinical testing for drug development in the United States and internationally. The company offers cellular and molecular technology instruments, such as syringe and peristaltic pump products, as well as a range of instruments and accessories for tissue and organ-based lab research, including surgical products, infusion systems, and behavior research systems; and spectrophotometers, microplate readers, amino acid analyzers, gel electrophoresis equipment, and electroporation and electrofusion instruments.

Featured Stories

Institutional Ownership by Quarter for Harvard Bioscience (NASDAQ:HBIO)

Receive News & Ratings for Harvard Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harvard Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.